Nonhuman primates
ADVERSE REACTIONS
Clinical signs were observed every 6 h from Days 0 to 10 post-challenge. On Days 11 through 28, clinical observations were recorded twice daily during normal business hours. Following the 28-day study period, surviving animals were transferred to the ABSL-2 facility. An additional twice-daily observation period of 60 days commenced for a total of 88 days of observations post-challenge. Monitoring for adverse reactions was done continuously during infusion of IGIV or ANTHRASIL and any adverse reactions were recorded.